Review



vemurafenib  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress vemurafenib
    A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, <t>vemurafenib,</t> and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.
    Vemurafenib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 130 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vemurafenib/product/MedChemExpress
    Average 94 stars, based on 130 article reviews
    vemurafenib - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning"

    Article Title: SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning

    Journal: NPJ Breast Cancer

    doi: 10.1038/s41523-025-00869-x

    A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, vemurafenib, and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.
    Figure Legend Snippet: A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, vemurafenib, and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.

    Techniques Used: Expressing, Marker, Flow Cytometry, Standard Deviation



    Similar Products

    vemurafenib  (MedChemExpress)
    94
    MedChemExpress vemurafenib
    A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, <t>vemurafenib,</t> and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.
    Vemurafenib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vemurafenib/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    vemurafenib - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    vemurafenib braf v600e medchemexpress g 5555 pak1 targetmol cobimetinib mek1 2 medchemexpress ulixertinib erk1 2 targetmol avutometinib  (MedChemExpress)
    94
    MedChemExpress vemurafenib braf v600e medchemexpress g 5555 pak1 targetmol cobimetinib mek1 2 medchemexpress ulixertinib erk1 2 targetmol avutometinib
    A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, <t>vemurafenib,</t> and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.
    Vemurafenib Braf V600e Medchemexpress G 5555 Pak1 Targetmol Cobimetinib Mek1 2 Medchemexpress Ulixertinib Erk1 2 Targetmol Avutometinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vemurafenib braf v600e medchemexpress g 5555 pak1 targetmol cobimetinib mek1 2 medchemexpress ulixertinib erk1 2 targetmol avutometinib/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    vemurafenib braf v600e medchemexpress g 5555 pak1 targetmol cobimetinib mek1 2 medchemexpress ulixertinib erk1 2 targetmol avutometinib - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    vemurafenib powder  (MedChemExpress)
    94
    MedChemExpress vemurafenib powder
    A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, <t>vemurafenib,</t> and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.
    Vemurafenib Powder, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vemurafenib powder/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    vemurafenib powder - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, vemurafenib, and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.

    Journal: NPJ Breast Cancer

    Article Title: SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning

    doi: 10.1038/s41523-025-00869-x

    Figure Lengend Snippet: A Correlation patterns among perturbagens within the HT class. The gradient from yellow to green indicates the range of correlation coefficients, with yellow denoting positive and green denoting negative correlations. B Expression patterns of the target and activated genes for five selected therapeutic candidates for breast cancer across various cell types. C Expression profiles of representative marker genes associated with breast cancer across six major breast cancer cell lines. D Cell viability shown by drugs (A-443654, buparlisib, celastrol, vemurafenib, and tozasertib) in breast cancer cells (MCF-7, HCC-1143, HCC-1954, T47D, and BT 474). Results are expressed as mean ± SD. E Flow cytometry (FACS) analysis of annexin expression in the HCC-1143 cell line treated with the pharmacological agent buparlisib. F Bar graph showing the proportion of apoptotic cells. Error bars indicate standard deviation from the mean.

    Article Snippet: A-443654 (CAS: 552325-16-3), Buparlisib (CAS: 944396-07-0), Celastrol (CAS: 34157-83-0), Tozasertib (CAS: 639089-54-6), and Vemurafenib (CAS: 918504-65-1) were purchased from MedChemExpress.

    Techniques: Expressing, Marker, Flow Cytometry, Standard Deviation